| | |
1 h increase in computer use time
|
p-value
|
None
|
≤1 h (reference)
|
1- ≤ 3 h
|
> 3 h
|
|---|
|
Person-years
| |
3,498,487
| |
969,721
|
1,744,785
|
582,168
|
201,813
|
|
Skin, melanoma
|
Cases
|
1621
| |
404
|
852
|
276
|
89
|
|
HR (95% CI)*
|
1.01 (0.98 1.05)
|
0.43**
|
0.77 (0.68 0.86)
|
1.00
|
0.90 (0.79 1.04)
|
0.92 (0.74 1.14)
|
| |
HR (95% CI)†
|
1.01 (0.97 1.05)
|
0.72
|
0.90 (0.79 1.02)
|
1.00
|
0.97 (0.85 1.12)
|
0.99 (0.79 1.24)
|
| |
HR (95% CI)a
|
1.01 (0.97 1.05)
|
0.73
|
0.91 (0.80 1.03)
|
1.00
|
0.98 (0.85 1.12)
|
0.996 (0.79 1.25)
|
|
Oropharyngeal
|
Cases
|
561
| |
209
|
239
|
88
|
25
|
| |
HR (95% CI)*
|
0.90 (0.84 0.97)
|
0.004
|
1.56 (1.29 1.88)
|
1.00
|
0.97 (0.76 1.23)
|
0.81 (0.54 1.23)
|
| |
HR (95% CI)†
|
0.93 (0.87 0.998)
|
0.04
|
1.27 (1.03 1.56)
|
1.00
|
0.91 (0.71 1.17)
|
0.77 (0.51 1.17)
|
| |
HR (95% CI)
|
0.93 (0.87 0.998)
|
0.04
|
1.27 (1.03 1.56)
|
1.00
|
0.91 (0.71 1.17)
|
0.77 (0.51 1.17)
|
|
Lung
|
Cases
|
2040
| |
894
|
700
|
316
|
130
|
|
HR (95% CI)*
|
0.97 (0.93 1.003)
|
0.08**
|
1.84 (1.66 2.03)
|
1.00
|
1.17 (1.03 1.34)
|
1.68 (1.39 2.03)
|
| |
HR (95% CI)†
|
1.02 (0.99 1.06)
|
0.16**
|
1.10 (0.99 1.23)
|
1.00
|
1.01 (0.88 1.16)
|
1.33 (1.10 1.62)
|
| |
HR (95% CI)h
|
1.02 (0.99 1.06)
|
0.16**
|
1.11 (0.99 1.24)
|
1.00
|
0.996 (0.87 1.15)
|
1.36 (1.12 1.65)
|
|
Breast (female only)
|
Cases
|
5650
| |
1728
|
2931
|
762
|
229
|
|
HR (95% CI)*
|
1.01 (0.99 1.03)
|
0.27**
|
0.93 (0.88 0.99)
|
1.00
|
1.02 (0.94 1.10)
|
0.997 (0.87 1.14)
|
| |
HR (95% CI)†
|
1.003 (0.98 1.03)
|
0.83**
|
0.97 (0.91 1.04)
|
1.00
|
0.999 (0.92 1.08)
|
1.001 (0.87 1.15)
|
| |
HR (95% CI)b, f, h
|
1.01 (0.98 1.03)
|
0.57**
|
0.96 (0.90 1.04)
|
1.00
|
0.998 (0.91 1.09)
|
1.03 (0.89 1.20)
|
|
Uterus
|
Cases
|
863
| |
315
|
389
|
127
|
32
|
| |
HR (95% CI)*
|
1.01 (0.95 1.07)
|
0.74
|
1.18 (1.02 1.38)
|
1.00
|
1.25 (1.03 1.53)
|
1.12 (0.78 1.60)
|
| |
HR (95% CI)†
|
0.96 (0.90 1.02)
|
0.20
|
1.18 (0.999 1.39)
|
1.00
|
1.04 (0.84 1.28)
|
0.91 (0.63 1.33)
|
| |
HR (95% CI)c
|
0.98 (0.92 1.04)
|
0.47
|
1.16 (0.98 1.37)
|
1.00
|
1.08 (0.87 1.35)
|
0.95 (0.64 1.40)
|
|
Ovary
|
Cases
|
567
| |
211
|
266
|
63
|
27
|
| |
HR (95% CI)*
|
0.98 (0.91 1.05)
|
0.51
|
1.16 (0.96 1.39)
|
1.00
|
0.91 (0.69 1.19)
|
1.36 (0.91 2.02)
|
| |
HR (95% CI)†
|
0.96 (0.89 1.04)
|
0.36
|
1.23 (1.01 1.50)
|
1.00
|
0.91 (0.69 1.21)
|
1.36 (0.91 2.04)
|
| |
HR (95% CI)
|
0.96 (0.89 1.04)
|
0.36
|
1.23 (1.01 1.50)
|
1.00
|
0.91 (0.69 1.21)
|
1.36 (0.91 2.04)
|
|
Prostate
|
Cases
|
5933
| |
1543
|
2699
|
1298
|
393
|
| |
HR (95% CI)*
|
1.005 (0.99 1.02)
|
0.61**
|
0.91 (0.85 0.97)
|
1.00
|
0.97 (0.91 1.03)
|
0.97 (0.87 1.07)
|
| |
HR (95% CI)†
|
0.998 (0.98 1.02)
|
0.85**
|
0.98 (0.92 1.06)
|
1.00
|
0.99 (0.93 1.06)
|
0.9998 (0.90 1.12)
|
| |
HR (95% CI)h
|
0.997 (0.98 1.02)
|
0.73**
|
0.99 (0.92 1.06)
|
1.00
|
0.99 (0.93 1.06)
|
0.99 (0.89 1.11)
|
|
Oesophagus
|
Cases
|
530
| |
174
|
221
|
108
|
27
|
| |
HR (95% CI)*
|
0.97 (0.90 1.03)
|
0.32
|
1.20 (0.98 1.47)
|
1.00
|
1.13 (0.90 1.42)
|
0.94 (0.63 1.41)
|
| |
HR (95% CI)†
|
0.97 (0.90 1.04)
|
0.37
|
0.99 (0.79 1.23)
|
1.00
|
1.02 (0.81 1.30)
|
0.78 (0.51 1.19)
|
| |
HR (95% CI)f
|
0.97 (0.90 1.04)
|
0.35
|
0.99 (0.79 1.23)
|
1.00
|
1.02 (0.80 1.30)
|
0.77 (0.51 1.18)
|
|
Stomach
|
Cases
|
349
| |
133
|
133
|
61
|
22
|
| |
HR (95% CI)*
|
0.98 (0.90 1.06)
|
0.60
|
1.50 (1.18 1.92)
|
1.00
|
1.09 (0.80 1.47)
|
1.30 (0.83 2.05)
|
| |
HR (95% CI)†
|
0.98 (0.91 1.07)
|
0.71
|
1.16 (0.88 1.51)
|
1.00
|
0.98 (0.72 1.35)
|
1.04 (0.64 1.69)
|
| |
HR (95% CI)
|
0.98 (0.91 1.07)
|
0.71
|
1.16 (0.88 1.51)
|
1.00
|
0.98 (0.72 1.35)
|
1.04 (0.64 1.69)
|
|
Oesophagus and stomach
|
Cases
|
873
| |
305
|
352
|
168
|
48
|
| |
HR (95% CI)*
|
0.97 (0.92 1.02)
|
0.25
|
1.31 (1.12 1.53)
|
1.00
|
1.11 (0.93 1.34)
|
1.06 (0.79 1.44)
|
| |
HR (95% CI)†
|
0.97 (0.92 1.03)
|
0.33
|
1.05 (0.89 1.25)
|
1.00
|
1.01 (0.83 1.22)
|
0.86 (0.62 1.19)
|
| |
HR (95% CI)f
|
0.97 (0.92 1.03)
|
0.32
|
1.05 (0.89 1.25)
|
1.00
|
1.01 (0.83 1.22)
|
0.86 (0.62 1.19)
|
|
Hepatobiliary tract
|
Cases
|
451
| |
170
|
168
|
91
|
22
|
| |
HR (95% CI)*
|
0.97 (0.90 1.04)
|
0.42
|
1.49 (1.20 1.85)
|
1.00
|
1.38 (1.07 1.79)
|
1.14 (0.73 1.77)
|
| |
HR (95% CI)†
|
0.99 (0.92 1.06)
|
0.74
|
1.21 (0.95 1.53)
|
1.00
|
1.30 (0.997 1.69)
|
1.02 (0.65 1.61)
|
| |
HR (95% CI)
|
0.99 (0.92 1.06)
|
0.74
|
1.21 (0.95 1.53)
|
1.00
|
1.30 (0.997 1.69)
|
1.02 (0.65 1.61)
|
|
Pancreatic
|
Cases
|
606
| |
189
|
276
|
114
|
27
|
| |
HR (95% CI)*
|
0.98 (0.92 1.05)
|
0.62
|
1.01 (0.83 1.21)
|
1.00
|
1.07 (0.86 1.34)
|
0.87 (0.59 1.29)
|
| |
HR (95% CI)†
|
0.98 (0.92 1.05)
|
0.62
|
0.90 (0.73 1.11)
|
1.00
|
1.05 (0.84 1.31)
|
0.76 (0.50 1.15)
|
| |
HR (95% CI)d
|
0.98 (0.92 1.05)
|
0.61
|
0.90 (0.73 1.10)
|
1.00
|
1.05 (0.84 1.31)
|
0.76 (0.50 1.14)
|
|
Kidney
|
Cases
|
783
| |
251
|
333
|
149
|
50
|
| |
HR (95% CI)*
|
1.01 (0.96 1.07)
|
0.60
|
1.17 (0.995 1.39)
|
1.00
|
1.12 (0.92 1.36)
|
1.23 (0.91 1.66)
|
| |
HR (95% CI)†
|
1.02 (0.97 1.08)
|
0.39**
|
1.04 (0.87 1.25)
|
1.00
|
1.05 (0.86 1.29)
|
1.19 (0.88 1.61)
|
| |
HR (95% CI)
|
1.02 (0.97 1.08)
|
0.39**
|
1.04 (0.87 1.25)
|
1.00
|
1.05 (0.86 1.29)
|
1.19 (0.88 1.61)
|
|
Bladder
|
Cases
|
670
| |
227
|
271
|
142
|
30
|
| |
HR (95% CI)*
|
0.98 (0.93 1.04)
|
0.54
|
1.22 (1.02 1.46)
|
1.00
|
1.18 (0.96 1.44)
|
0.85 (0.59 1.25)
|
| |
HR (95% CI)†
|
0.97 (0.92 1.04)
|
0.41**
|
1.09 (0.89 1.32)
|
1.00
|
1.08 (0.87 1.33)
|
0.76 (0.51 1.13)
|
| |
HR (95% CI)
|
0.97 (0.92 1.04)
|
0.41**
|
1.09 (0.89 1.32)
|
1.00
|
1.08 (0.87 1.33)
|
0.76 (0.51 1.13)
|
|
Colorectal
|
Cases
|
3312
| |
1059
|
1512
|
556
|
185
|
| |
HR (95% CI)*
|
0.99 (0.96 1.02)
|
0.45**
|
1.07 (0.99 1.16)
|
1.00
|
0.95 (0.87 1.05)
|
1.05 (0.90 1.23)
|
| |
HR (95% CI)†
|
0.99 (0.96 1.01)
|
0.31**
|
1.08 (0.99 1.18)
|
1.00
|
0.95 (0.86 1.05)
|
1.03 (0.88 1.21)
|
| |
HR (95% CI)e, g, f (males)
|
0.98 (0.96 1.01)
|
0.28**
|
1.06 (0.97 1.16)
|
1.00
|
0.95 (0.86 1.05)
|
1.02 (0.87 1.20)
|
|
Colon
|
Cases
|
2124
| |
681
|
980
|
348
|
115
|
| |
HR (95% CI)*
|
0.99 (0.96 1.03)
|
0.63**
|
1.04 (0.94 1.15)
|
1.00
|
0.94 (0.83 1.06)
|
1.04 (0.86 1.26)
|
| |
HR (95% CI)†
|
0.99 (0.95 1.02)
|
0.50**
|
1.04 (0.93 1.15)
|
1.00
|
0.93 (0.82 1.06)
|
1.02 (0.83 1.24)
|
| |
HR (95% CI)e, g, f (males)
|
0.99 (0.95 1.02)
|
0.42**
|
1.03 (0.92 1.14)
|
1.00
|
0.93 (0.82 1.06)
|
1.02 (0.83 1.25)
|
|
Rectum
|
Cases
|
1115
| |
354
|
501
|
195
|
65
|
| |
HR (95% CI)*
|
0.98 (0.94 1.03)
|
0.42**
|
1.12 (0.98 1.29)
|
1.00
|
0.97 (0.82 1.14)
|
1.04 (0.80 1.35)
|
| |
HR (95% CI)†
|
0.97 (0.93 1.02)
|
0.28
|
1.20 (1.03 1.39)
|
1.00
|
0.97 (0.82 1.15)
|
1.03 (0.79 1.35)
|
| |
HR (95% CI)e, g
|
0.97 (0.93 1.02)
|
0.28
|
1.16 (0.999 1.36)
|
1.00
|
0.96 (0.81 1.15)
|
0.999 (0.76 1.32)
|
|
Thyroid
|
Cases
|
237
| |
82
|
106
|
35
|
14
|
| |
HR (95% CI)*
|
1.02 (0.92 1.12)
|
0.76
|
1.31 (0.98 1.76)
|
1.00
|
1.10 (0.75 1.61)
|
1.32 (0.76 2.31)
|
| |
HR (95% CI)†
|
1.01 (0.91 1.11)
|
0.86
|
1.36 (0.99 1.87)
|
1.00
|
1.08 (0.73 1.59)
|
1.28 (0.73 2.25)
|
| |
HR (95% CI)
|
1.01 (0.91 1.11)
|
0.86
|
1.36 (0.99 1.87)
|
1.00
|
1.08 (0.73 1.59)
|
1.28 (0.73 2.25)
|
|
Brain tumours
|
Cases
|
463
| |
130
|
221
|
87
|
25
|
| |
HR (95% CI)*
|
1.02 (0.95 1.09)
|
0.62
|
0.95 (0.77 1.19)
|
1.00
|
1.02 (0.79 1.31)
|
0.93 (0.61 1.40)
|
| |
HR (95% CI)†
|
1.03 (0.96 1.10)
|
0.39
|
0.92 (0.72 1.17)
|
1.00
|
1.03 (0.80 1.34)
|
0.96 (0.63 1.47)
|
| |
HR (95% CI)f
|
1.03 (0.96 1.10)
|
0.38
|
0.92 (0.72 1.17)
|
1.00
|
1.04 (0.80 1.34)
|
0.97 (0.63 1.48)
|
|
Haematological malignancies
|
Cases
|
2446
| |
714
|
1137
|
445
|
150
|
| |
HR (95% CI)*
|
1.03 (0.998 1.06)
|
0.06
|
0.95 (0.87 1.05)
|
1.00
|
1.02 (0.92 1.14)
|
1.14 (0.96 1.36)
|
| |
HR (95% CI)†
|
1.02 (0.99 1.05)
|
0.24
|
0.95 (0.86 1.06)
|
1.00
|
0.997 (0.89 1.12)
|
1.11 (0.93 1.32)
|
| |
HR (95% CI)
|
1.02 (0.99 1.05)
|
0.24
|
0.95 (0.86 1.06)
|
1.00
|
0.997 (0.89 1.12)
|
1.11 (0.93 1.32)
|
|
Non-Hodgkin’s lymphoma
|
Cases
|
1182
| |
349
|
545
|
225
|
63
|
| |
HR (95% CI)*
|
1.02 (0.98 1.06)
|
0.37
|
0.97 (0.85 1.11)
|
1.00
|
1.09 (0.94 1.28)
|
1.02 (0.78 1.32)
|
| |
HR (95% CI)†
|
1.01 (0.97 1.06)
|
0.65
|
0.996 (0.86 1.15)
|
1.00
|
1.07 (0.91 1.26)
|
1.03 (0.79 1.34)
|
| |
HR (95% CI)
|
1.01 (0.97 1.06)
|
0.65
|
0.996 (0.86 1.15)
|
1.00
|
1.07 (0.91 1.26)
|
1.03 (0.79 1.34)
|
- *Models adjusted for age and sex (total observations = 467,656)
- †Models adjusted for age, sex, ethnicity (white/other), deprivation index (quintiles), education (University degree, A-levels/HNC/HND/NVQ, GCSE/O-level/CSE, OTHER, None), fruit and vegetable intake (< 5 portions/day, ≥5 portions/day), BMI (kg/m2), height (m), smoking status (never, former light smoker [< 20 pack-years], former heavy smoker [≥20 pack-years], current light smoker [< 20 pack-years], current heavy smoker [≥20 pack-years]) and alcohol intake (never, former, current [<once/week], current [≥once/week])
- aAdditional site-specific covariates in the final model include use of sun/UV protection (Never/rarely/sometimes; most of the time/always; do not go out in sunshine)
- bAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
- cAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
- dAdditional site-specific covariates in the final model include diabetes at baseline (yes/no)
- eAdditional site-specific covariates in the final model include diabetes at baseline (yes/no), aspirin use (regular use/non-regular use or no use), HRT use (ever used/never used; females only), red meat intake (portion/week), processed meat intake (portion/week)
- fFinal model also adjusted for waist-hip ratio (> 94 cm in men, > 80 cm in women)
- f(males)For cancer sites which were adjusted for different sets of covariates for males and females (colorectal, colon, rectum), this indicates that the final model for male participants was also adjusted for waist-hip ratio (> 94 cm in men)
- gResults for males and females combined using meta-analysis as covariates are different
- hFinal model also adjusted for family history of cancer (mother/father/sibling had cancer, no family history)
- **Schoenfeld test indicated potential violation of the proportional hazards assumption (p < 0.05)
